Evotec announces update on DiaPep277
In a press release published by Hyperion on 08 September 2014 at market opening in the US, the company states that it has uncovered evidence that certain employees of Andromeda Biotech, Ltd., which Hyperion acquired in June 2014, engaged in serious misconduct, involved with the trial data of DiaPep277®. Hyperion announced that it will complete the DIA-AID 2 Phase 3 trial, but will terminate further development in DiaPep277®.
DiaPep277® is one of Evotec's advanced pipeline projects, where Evotec is entitled to royalties and milestones. Given the situation of the programme Evotec does no longer expect this project to hit the market. Therefore, the company expects to record a non-cash impairment charge of EUR 8.7 m.
In addition, Evotec still has an open receivable against Andromeda/Hyperion, which amounts to EUR 3.4 m, the payment of which is required for Evotec to meet its profitability in 2014.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.